Home » Topics » BioWorld Science

BioWorld Science
RSS

Large-scale mapping uncovers protein interactions

July 15, 2019

FibroGen reports phase II data for pamrevlumab in patients with DMD

July 15, 2019

How mothers drive their offspring to drink

July 15, 2019

CD73 target defined for subgroup of AML precision medicine

July 15, 2019

Roche presents interim results from part 1 of FIREFISH study of risdiplam

July 15, 2019

Results presented from phase III EAT2TREAT study of fampridine and acetazolamide

July 15, 2019

Recruitment ongoing in phase I study of BI-836880 for the treatment of wAMD

July 15, 2019

EIP Pharma initiates phase II study of neflamapimod in cognitive dysfunction associated with DLB

July 15, 2019

Allist Pharmaceuticals initiates phase III FLAG study of alflutinib mesylate in NSCLC

July 15, 2019

Slt-deficient F. novicida mutant shows attenuation and protects against pneumonic challenge in mice

July 15, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...